Alamar Biosciences, Inc. has 6 Schedule 13D or 13G filings on record since 2026-04-23. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Qiming Corporate GP VI, Ltd | 10.2% | 7,066,573 | SCHEDULE 13G, 2026-08-11 | 2026-06-30 |
| Illumina Innovation Fund II, L.P. | 9.6% | 5,856,536 | SCHEDULE 13D, 2026-04-23 | 2026-04-20 |
| Daqing Cai | 7.2% | 4,972,134 | SCHEDULE 13G, 2026-07-02 | 2026-04-16 |
| Yuling Luo | 6.4% | 4,528,718 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.1% | 4,230,926 | SCHEDULE 13D/A, 2026-07-07 | 2026-07-05 |
Purpose of Transaction (Item 4)
Illumina Innovation Fund II, L.P.
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Nicholas Naclerio is a member of the Issuer's board of directors. In addition, Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-23; the filing has the rest
Sands Capital Life Sciences Pulse Fund II, L.P.
Item 4 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Persons acquired and hold the Common Stock for investment purposes in the ordinary course of Sands Pulse Fund II's investment activities. Subject to applicable legal requirements or contractual restrictions, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions depending on their evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. Consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer and/or members of the board of directors of the Issuer, to discuss matters regarding the Issuer including but not limited to its operations and strategic …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-23 | Illumina Innovation Fund II, L.P. | 9.6% | SCHEDULE 13D |
| 2026-04-23 | Sands Capital Life Sciences Pulse Fund II, L.P. | 6.3% | SCHEDULE 13D |
| 2026-07-02 | Daqing Cai | 7.2% | SCHEDULE 13G |
| 2026-07-07 | Sands Capital Life Sciences Pulse Fund II, L.P. | 6.1% | SCHEDULE 13D/A |
| 2026-08-11 | Qiming Corporate GP VI, Ltd | 10.2% | SCHEDULE 13G |
| 2026-08-13 | Yuling Luo | 6.4% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Alamar Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.